Contrasting MariMed (MRMD) & Its Peers

MariMed (OTCMKTS:MRMDGet Rating) is one of 49 publicly-traded companies in the “Medicinals & botanicals” industry, but how does it contrast to its peers? We will compare MariMed to related businesses based on the strength of its risk, valuation, institutional ownership, analyst recommendations, dividends, profitability and earnings.

Institutional and Insider Ownership

0.3% of MariMed shares are held by institutional investors. Comparatively, 16.3% of shares of all “Medicinals & botanicals” companies are held by institutional investors. 20.0% of MariMed shares are held by company insiders. Comparatively, 26.3% of shares of all “Medicinals & botanicals” companies are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for MariMed and its peers, as reported by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
MariMed 0 0 2 0 3.00
MariMed Competitors 276 683 679 29 2.28

MariMed currently has a consensus target price of $2.25, suggesting a potential upside of 262.90%. As a group, “Medicinals & botanicals” companies have a potential upside of 131.06%. Given MariMed’s stronger consensus rating and higher possible upside, equities analysts plainly believe MariMed is more favorable than its peers.

Valuation and Earnings

This table compares MariMed and its peers top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
MariMed $121.46 million $7.22 million 31.02
MariMed Competitors $238.87 million -$88.85 million -7.42

MariMed’s peers have higher revenue, but lower earnings than MariMed. MariMed is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Risk & Volatility

MariMed has a beta of 3.27, meaning that its share price is 227% more volatile than the S&P 500. Comparatively, MariMed’s peers have a beta of 1.49, meaning that their average share price is 49% more volatile than the S&P 500.


This table compares MariMed and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
MariMed 5.70% 22.73% 6.36%
MariMed Competitors -165.36% -257.06% -16.07%


MariMed beats its peers on 9 of the 13 factors compared.

MariMed Company Profile (Get Rating)

MariMed Inc. engages in cultivation, production, and dispensing of medicinal and recreational cannabis in the United States and internationally. The company offers cannabis genetics produce flowers and concentrates under the Nature's Heritage brand; cannabis-infused products in the form of chewable tablets and powder drink mixes under the brand Kalm Fusion; natural fruit chews under the Betty's Eddies brand; brownies, cookies, and other social sweets under the Bubby's Baked brand; and cannabidiol formulations under the Florance brand. It also licenses its brands and product formulations, as well as leases cannabis facilities. MariMed Inc. was incorporated in 2011 and is based in Norwood, Massachusetts.

Receive News & Ratings for MariMed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MariMed and related companies with's FREE daily email newsletter.